- Diabetes mellitus Type 2
- Currently treated with at least 2 oral anti-diabetic agents
- Severe Asthma, severe COPD
- Smoking
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based formula.
- Diabetes mellitus Type 2
- Currently treated with at least 2 oral anti-diabetic agents
- Severe Asthma, severe COPD
- Smoking
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021